These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37621050)

  • 1. Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults.
    Zhang Y; Joshi S; Yazdani P; Zhan J; Wen B; Bainbridge V; Ballesteros-Perez A; Gartland M; Lataillade M
    Br J Clin Pharmacol; 2024 Jan; 90(1):274-285. PubMed ID: 37621050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants.
    Zhang Y; Johnson M; Joshi S; Yazdani P; Zhan J; Wen B; Bainbridge V; Gartland M; Lataillade M
    Br J Clin Pharmacol; 2023 Jul; 89(7):2236-2245. PubMed ID: 36822839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
    Larson KB; Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Acosta EP;
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):131-7. PubMed ID: 27199469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.
    Song I; Borland J; Min S; Lou Y; Chen S; Patel P; Wajima T; Piscitelli SC
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3517-21. PubMed ID: 21555764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.
    Mathias AA; Hinkle J; Shen G; Enejosa J; Piliero PJ; Sekar V; Mack R; Tomaka F; Kearney BP
    J Acquir Immune Defic Syndr; 2008 Oct; 49(2):156-62. PubMed ID: 18769354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
    Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
    Clin Drug Investig; 2008; 28(8):479-85. PubMed ID: 18598093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254.
    Spinner CD; Felizarta F; Rizzardini G; Philibert P; Mitha E; Domingo P; Stephan CJ; DeGrosky M; Bainbridge V; Zhan J; Dumitrescu TP; Jeffrey JL; Xu J; Halliday F; Gan J; Johnson M; Gartland M; Joshi SR; Lataillade M
    Clin Infect Dis; 2022 Sep; 75(5):786-794. PubMed ID: 34996113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the HIV-1 maturation inhibitor GSK3640254 on QT interval in healthy participants.
    Zhang Y; Bush M; Yazdani P; Zhan J; Wen B; Bainbridge V; Wynne BR; Joshi S; Lataillade M
    Pharmacol Res Perspect; 2023 Dec; 11(6):e01151. PubMed ID: 37961928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.
    Malvestutto CD; Ma Q; Morse GD; Underberg JA; Aberg JA
    J Acquir Immune Defic Syndr; 2014 Dec; 67(4):390-6. PubMed ID: 25202920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
    Moltó J; Curran A; Miranda C; Challenger E; Santos JR; Ribera E; Khoo S; Valle M; Clotet B
    J Antimicrob Chemother; 2018 Mar; 73(3):732-737. PubMed ID: 29237008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
    Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
    Sekar VJ; Lefebvre E; De Paepe E; De Marez T; De Pauw M; Parys W; Hoetelmans RM
    Antimicrob Agents Chemother; 2007 Mar; 51(3):958-61. PubMed ID: 17210768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.
    Sekar V; Lavreys L; Van de Casteele T; Berckmans C; Spinosa-Guzman S; Vangeneugden T; De Pauw M; Hoetelmans R
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4440-5. PubMed ID: 20660678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults.
    Arathoon E; Bhorat A; Silaghi R; Crauwels H; Lavreys L; Tambuyzer L; Vanveggel S; Opsomer M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19783. PubMed ID: 25397527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; Sekar V; Woodfall B; De Smedt G; Lefebvre E; Peeters M; Hoetelmans RM
    Antivir Ther; 2007; 12(5):789-96. PubMed ID: 17713162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone.
    Boyd SD; Hadigan C; McManus M; Chairez C; Nieman LK; Pau AK; Alfaro RM; Kovacs JA; Calderon MM; Penzak SR
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):355-61. PubMed ID: 23535292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial.
    Abdalla S; Compagnucci A; Riault Y; Chan MK; Bamford A; Nolan A; Ramos JT; Constant V; Nguyen T-N; Zheng Y; Tréluyer J-M; Froelicher-Bournaud L; Neveux N; Saidi Y; Cressey TR; Hirt D;
    Antimicrob Agents Chemother; 2024 Feb; 68(2):e0100423. PubMed ID: 38092664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
    Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.